Thrombolytic therapy in acute myocardial infarction

Area of Science:

• Cardiology
• Emergency Medicine
• Pharmacology

Background:

• Acute myocardial infarction (AMI) is a leading cause of mortality.
• Early reperfusion therapy, including thrombolysis, is crucial for improving outcomes in AMI.
• Identifying optimal candidates and agents for thrombolytic therapy remains an area of active research.

Purpose of the Study:

• To review the effectiveness and safety of thrombolytic agents in acute myocardial infarction.
• To compare different thrombolytic drugs, including streptokinase, alteplase, and anistreplase.
• To outline patient selection criteria, contraindications, and adjunctive therapies for thrombolytic treatment.

Main Methods:

• Review of multiple clinical trials and recent studies on thrombolytic therapy for AMI.
• Comparative analysis of the efficacy, cost, administration routes, and adverse effects of streptokinase, alteplase, and anistreplase.
• Identification of contraindications and recommended adjunctive treatments.

Main Results:

• Thrombolytic treatment initiated early in AMI significantly reduces mortality.
• Patients under 75 with chest pain ≤6 hours and ST-segment elevation are ideal candidates.
• Streptokinase is cost-effective and has a lower risk of intracranial bleeding compared to alteplase and anistreplase.
• Anistreplase offers a rapid bolus administration advantage.
• Contraindications include pregnancy, active bleeding, uncontrolled hypertension, and history of hemorrhagic stroke.
• Heparin is recommended with alteplase and streptokinase; aspirin, beta blockers, nitrates, and lidocaine are useful adjuncts.

Conclusions:

• Early thrombolytic therapy is a cornerstone in managing acute myocardial infarction.
• Streptokinase presents a favorable risk-benefit profile regarding cost and safety.
• Careful patient selection and appropriate use of adjunctive therapies are essential for optimal outcomes.